Join Growin Stock Community!

Silence therapeutics plcSLN.US Overview

US StockHealthcare
(No presentation for SLN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SLN AI Insights

SLN Overall Performance

SLN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SLN Recent Performance

11.76%

Silence therapeutics plc

0.05%

Avg of Sector

-0.31%

S&P500

SLN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SLN Key Information

SLN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SLN Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Price of SLN

SLN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SLN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9.95
PB Ratio
2.61
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
90.49%
Net Margin
-255.12%
Revenue Growth (YoY)
28.53%
Profit Growth (YoY)
159.76%
3-Year Revenue Growth
-66.46%
3-Year Profit Growth
-72.67%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9.95
PB Ratio
2.61
Price-to-FCF
-
Gross Margin
90.49%
Net Margin
-255.12%
Revenue Growth (YoY)
28.53%
Profit Growth (YoY)
159.76%
3-Year Revenue Growth
-66.46%
3-Year Profit Growth
-72.67%

  • When is SLN's latest earnings report released?

    The most recent financial report for Silence therapeutics plc (SLN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SLN's short-term business performance and financial health. For the latest updates on SLN's earnings releases, visit this page regularly.

  • What is the operating profit of SLN?

    According to the latest financial report, Silence therapeutics plc (SLN) reported an Operating Profit of -26.24M with an Operating Margin of -16,505.66% this period, representing a growth of 6.84% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SLN's revenue growth?

    In the latest financial report, Silence therapeutics plc (SLN) announced revenue of 159K, with a Year-Over-Year growth rate of -88.86%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does SLN have?

    As of the end of the reporting period, Silence therapeutics plc (SLN) had total debt of 182K, with a debt ratio of 0. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SLN have?

    At the end of the period, Silence therapeutics plc (SLN) held Total Cash and Cash Equivalents of 82.03M, accounting for 0.56 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SLN go with three margins increasing?

    In the latest report, Silence therapeutics plc (SLN) did not achieve the “three margins increasing” benchmark, with a gross margin of 59.7%%, operating margin of -16,505.66%%, and net margin of -13,181.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SLN's profit trajectory and future growth potential.

  • Is SLN's EPS continuing to grow?

    According to the past four quarterly reports, Silence therapeutics plc (SLN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.45. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SLN?

    Silence therapeutics plc (SLN)'s Free Cash Flow (FCF) for the period is -10.89M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 55.77% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SLN?

    The latest valuation data shows Silence therapeutics plc (SLN) has a Price-To-Earnings (PE) ratio of -4.58 and a Price/Earnings-To-Growth (PEG) ratio of -0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.